MENU

HBIO Stock Tickeron detected bullish Stock Pattern: Head-and-Shoulders Bottom on April 25, 2025

A.I.dvisor
at Tickeron.com
Loading...
Head-and-Shoulders Bottom
HBIO - Harvard Bioscience
Tickeron
Emerged: 04/25/25
Breakout: $0.39905
Price: $0.3899
Target price: $0.4339
A.I.dvisor detected a bullish Head-and-Shoulders Bottom pattern for HBIO stock. This pattern was detected on April 25, 2025 . The odds of reaching the target price are 8. The Head-and-Shoulders Bottom pattern is formed when the price of a security creates a center trough (the inverted head, labeled 3) and the left and right inverted shoulders (1, 5). After reaching the lowest low (the Head, 3) the next low is shallower and the trend reverses course to the upside. Consider buying a security or a call option at the low once the pattern is confirmed, which is known as the breakout point. The pattern is confirmed when the price breaks above the Neckline (2,4).

HBIO's RSI Oscillator climbs out of oversold territory

The RSI Indicator for HBIO moved out of oversold territory on April 22, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In of the 31 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HBIO advanced for three days, in of 249 cases, the price rose further within the following month. The odds of a continued upward trend are .

HBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on April 24, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on HBIO as a result. In of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for HBIO entered a downward trend on April 17, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.530) is normal, around the industry mean (10.413). P/E Ratio (0.000) is within average values for comparable stocks, (81.243). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (1.610) is also within normal values, averaging (41.902).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. HBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.

View a ticker or compare two or three
HBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of apparatus and scientific instruments

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Biotechnology
Address
84 October Hill Road
Phone
+1 508 893-8999
Employees
416
Web
https://www.harvardbioscience.com